In an era when physicians must balance bleeding risk and ischemic events risk in AF patients undergoing PCI, our network meta-analysis demonstrates that dual therapy with NOACs and P2Y12 inhibitors is better than conventional triple therapy for bleeding outcomes, and comparable in terms of efficacy outcomes. This evidence concerns the gene P2RY12 and atrial fibrillation.